Targeting Myasthenia Gravis with Antigen-Specific Immune Tolerance Approaches for a Durable, Disease Modifying Treatment
Time: 10:30 am
day: Conference Day One
Details:
• Inducing immune tolerance in MG disease patients with a nanoparticle-based immune tolerizing therapy encapsulating gliadin proteins
• Delving into the design of clinical trials for efficacy – considering the interplay of accurate disease modeling and good standard of care with administering a tolerizing therapy
• Assessing the durability and necessary dosage to induce immune tolerance in the digestive system
